Drug Discovery World

OCTOBER 20, 2023

GenomeFrontier’s Founder and CEO/CSO, Sareina Wu, said: “We believe that a cancer-free world is not only possible but is more real than ever before, due to major advancements in gene therapy. Anders Grøn, CEO at Clinical Microbiomics, said: “We are a company made up of scientists – Innovation is at the heart of our DNA.

Drugs 52

Drugs Antibody DNA Gene Therapy 52

Drug Discovery World

NOVEMBER 30, 2023

Cell and gene therapy developer eXmoor pharma has hired Matthew Paterson as the company’s first Chief Commercial Officer, moving on from 18 years at Quotient Sciences. She is currently Professor of Structural Bioinformatics at the University of Oxford and Chief AI Officer at Exscientia.

Drugs 52

Drugs Genome Genomics Bioinformatics 52

pharmaphorum

APRIL 15, 2021

We have a pipeline of novel therapeutics and technological approaches, advancing a diverse array of candidates, including small molecules, biologics and cell and gene therapies, so a lot of the time we are working where there’s little, or no precedent.”. In principle, this goes beyond medicines.

Development 63

Development Manufacturing Production Bioinformatics 63

Drug Discovery World

APRIL 29, 2024

Jean-Baptiste Agnus, Chief Business Officer, and Peter Carbone, Chief Quality Officer, KBI Biopharma: Agnus brings more than two decades of experience in the biopharmaceutical industry with expertise in biologics, small molecule APIs, antibody-drug conjugates (ADCs), and cell and gene therapies.

Drugs 52

Drugs Sales Gene Therapy Life Science 52

Scienmag

NOVEMBER 12, 2020

In a study that has unprecedented implications to advance both medicine and biodiversity conservation, researchers have sequenced 131 new placental mammal genomes, bringing the worldwide total to more than 250 In a study that has unprecedented implications to advance both medicine and biodiversity conservation, researchers have sequenced 131 new placental (..)

Biobanking 41

Biobanking Medicine Genome Genomics 41

Drug Discovery World

NOVEMBER 13, 2023

Novel/alternative ML-enabled screening technologies for higher POS Following chairperson’s remarks from M Frank Erasmus, PhD, Head, Bioinformatics, Specifica, there will be four presentations and a panel discussion.

Protein 59

Protein Antibody Engineer Scientist 59

Drug Discovery World

NOVEMBER 9, 2023

Charlotte Deane, PhD, Professor, Structural Bioinformatics, Statistics, University of Oxford; Chief Scientist, Biologics AI, Exscientia, giving a featured presentation on generative antibody modelling. The session ends with two presentations and two luncheon presentations.

Engineer 52

Engineer Antibody Protein In-Vivo 52

Drug Discovery World

OCTOBER 17, 2022

For pharma and biotech companies – whether working on small or large molecule drugs, or cell and gene therapies – this means empowering scientists with better and faster data management approaches, best practices, and leading technologies so they can pinpoint new molecules and formulations and modify existing ones more easily and quickly.

Marketing 52

Marketing Scientist Gene Expression Drugs 52